Silcura® IAD (incontinence-associated dermatitis)
In observational studies, Silcura® spray was shown to be effective against both diaper dermatitis in babies and incontinence-associated dermatitis in those needing long-term care, e. g. Parkinson’s patients. In other cases, involving incontinent stroke patients on a neurological ward, the nursing staff were able to see very good results over a period of four weeks. Two 125 ml Silcura® spray dispensers were sufficient to cover this interval, at a rate of two applications per day. In this application study, the nursing staff reported considerable improvements in the condition of the skin in the genital area and in skin folds, as well as a significant reduction in odor.
Incontinence-associated dermatitis (IAD) is an irritant toxic contact dermatitis. Continuous contact with urine and feces irritates the skin, causing rashes or eczema to develop, for example, right through to dermatitis, whereupon the skin becomes highly inflamed all around the affected areas. Moisture, irritants and micro-organisms trigger this inflammation and lead to skin damage in the genital area.
Where is Silcura® available?
Silcura® is currently available on the Latin-American market and, under the brand names PelCare® Silber and Belcura®, in Europe.